Status:

SUSPENDED

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

Lead Sponsor:

Sandoz

Conditions:

Melanoma

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of the study is to demonstrate similar PK and efficacy and to show comparable safety and immunogenicity between JPB898, Opdivo-EU, and Opdivo-US, all administered in combination with Yervo...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Male or female participants must be 18 years or older.
  • Histologically confirmed melanoma.
  • Unresectable or metastatic melanoma measurable by Computerized tomography (CT) or Magnetic resonance imaging (MRI).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Known Programmed cell death ligand 1 (PD-L1) and BRAF mutational status or consent to testing.
  • Sexually active participants must agree to use effective contraception.
  • Exclusion Criteria
  • Active brain or leptomeningeal metastases unless stable for 8 weeks.
  • Ocular melanoma.
  • Prior active malignancy within the last year untreated or still requiring treatment.
  • Severe and uncontrolled conditions, active Hepatitis B/C, Human immunodeficiency virus (HIV), or autoimmune diseases requiring systemic treatment.
  • Previous treatment with specific immune checkpoint inhibitors, systemic anticancer therapy, or radiotherapy for melanoma.

Exclusion

    Key Trial Info

    Start Date :

    December 19 2024

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    February 1 2026

    Estimated Enrollment :

    720 Patients enrolled

    Trial Details

    Trial ID

    NCT06587451

    Start Date

    December 19 2024

    End Date

    February 1 2026

    Last Update

    August 7 2025

    Active Locations (57)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 15 (57 locations)

    1

    Sandoz Investigational Site

    Sofia, Bulgaria

    2

    Sandoz Investigational Site

    Providencia, Chile

    3

    Sandoz Investigational Site

    Santiago, Chile

    4

    Sandoz Investigational Site

    Viña del Mar, Chile